Awaiting summarization
Will a new Russian migraine drug undergo clinical trials by the end of 2026?
Volume~$207
YES chance
DescriptionRussian scientists have presented a unique molecule with antiserotonin activity that targets the 5-HT2A receptor. The developers claim that this mechanism outperforms existing triptans (which have an efficacy of 65–75%) and has no global counterparts. A series of clinical trials in humans is required to bring the drug to market. The key question is whether the Russian Ministry of Health will grant official approval to conduct clinical trials (CTs) of this specific drug by the end of this year.
ConditionsYes: if, by December 31, 2026, an entry is made in the State Register of Medicines (GRLS) regarding the issuance of a clinical trial authorization for a new drug with an antiserotonin effect (5-HT2A receptor).
No: if official authorization for the clinical trial has not been obtained by the end of 2026.
Timeline
OpenedMar 24, 2026, 9:57 PM
Closes
Jun 30, 2026, 8:59 PMChecking results
—EndsJan 1, 2027, 8:59 PM
OpenedMar 24, 2026, 9:57 PM
Closes
Jun 30, 2026, 8:59 PMChecking results
—EndsJan 1, 2027, 8:59 PM
ActivityView all
Top poll holdersView all
Voted for YES
#
User
Vol.
1
buba
buba16 BPCX
2
111
11114 BPCX
3
ConicMalraux
ConicMalraux6 BPCX
4
FirmGang
FirmGang5 BPCX
5
MMTrader
MMTrader2 BPCX
Voted for NO
#
User
Vol.
1
NastyAeolis
NastyAeolis27 BPCX
2
wEEd
wEEd23 BPCX
3
5kkkkkkusdt
5kkkkkkusdt22 BPCX
4
joS_edge
joS_edge21 BPCX
5
BlitheWits
BlitheWits16 BPCX
Awaiting summarization
Will a new Russian migraine drug undergo clinical trials by the end of 2026?
Volume~$207
DescriptionRussian scientists have presented a unique molecule with antiserotonin activity that targets the 5-HT2A receptor. The developers claim that this mechanism outperforms existing triptans (which have an efficacy of 65–75%) and has no global counterparts. A series of clinical trials in humans is required to bring the drug to market. The key question is whether the Russian Ministry of Health will grant official approval to conduct clinical trials (CTs) of this specific drug by the end of this year.
ConditionsYes: if, by December 31, 2026, an entry is made in the State Register of Medicines (GRLS) regarding the issuance of a clinical trial authorization for a new drug with an antiserotonin effect (5-HT2A receptor).
No: if official authorization for the clinical trial has not been obtained by the end of 2026.
Event results
No results yet